<DOC>
	<DOC>NCT02309320</DOC>
	<brief_summary>The primary objective of the study is to investigate the safety and tolerability of ALX-0171. The secondary objectives are to evaluate the clinical effect of ALX-0171 and to explore the pharmacodynamics (PD) and the systemic pharmacokinetics (PK) of ALX-0171.</brief_summary>
	<brief_title>A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>1. Subject is otherwise healthy, but hospitalised for and clinically diagnosed with RSV LRTI (Lower Respiratory Tract Infection) 2. Subject has appearance of upper or lower respiratory tract infection symptoms that are likely related to RSV 3. Subject has a positive RSV diagnostic test 4. Others as defined in the protocol 1. Subject has history of wheezing 2. Subject is known to have significant comorbidities 3. Subject is known to be immunocompromised 4. Subject is suspected of having a clinically relevant infection other than RSV 5. Others as defined in the protocol</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>